TR200100863T2 - (2S,3S,5R)-2-(3,5-Diflorofenil)-3,5-dimetil-2-morfolinol ve etkili dengeleyici miktarda alginik asit içeren oral dozaj formülasyonları. - Google Patents

(2S,3S,5R)-2-(3,5-Diflorofenil)-3,5-dimetil-2-morfolinol ve etkili dengeleyici miktarda alginik asit içeren oral dozaj formülasyonları.

Info

Publication number
TR200100863T2
TR200100863T2 TR2001/00863T TR200100863T TR200100863T2 TR 200100863 T2 TR200100863 T2 TR 200100863T2 TR 2001/00863 T TR2001/00863 T TR 2001/00863T TR 200100863 T TR200100863 T TR 200100863T TR 200100863 T2 TR200100863 T2 TR 200100863T2
Authority
TR
Turkey
Prior art keywords
morpholinol
difluorophenyl
dimethyl
alginic acid
oral dosage
Prior art date
Application number
TR2001/00863T
Other languages
English (en)
Inventor
Bruce Balik Samuel
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200100863T2 publication Critical patent/TR200100863T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bu bulus (2S, 3S, 5R)-2-(3,5-diflorofenil)-3,5-dimetil-2-morfolinol veya bunun fizyolojik olarak uygun bir tuzunu veya çözünmüs halini, veya bahsedilen tuzun bir çözünmüs halini ve alginik asidin etkili dayaniklilik saglayici bir miktarini içeren tipik olarak tabletler veya kapsüller olan ayri oral dozaj formlari saglar. Bu dozaj formlari dikkat eksikligi hiperkinezi bozuklugu veya depresyonun önlenmesi veya tedavi edilmesinde, nikotin içeren ürünlere bagimliligin tedavisinde, örnegin sigaranin birakilmasina yardimci olmasi için, özellikle tütün içeren ürünlere bagimliligin tedavi edilmesinde yararlidir.
TR2001/00863T 1998-09-28 1999-09-24 (2S,3S,5R)-2-(3,5-Diflorofenil)-3,5-dimetil-2-morfolinol ve etkili dengeleyici miktarda alginik asit içeren oral dozaj formülasyonları. TR200100863T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10211298P 1998-09-28 1998-09-28

Publications (1)

Publication Number Publication Date
TR200100863T2 true TR200100863T2 (tr) 2001-07-23

Family

ID=22288187

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00863T TR200100863T2 (tr) 1998-09-28 1999-09-24 (2S,3S,5R)-2-(3,5-Diflorofenil)-3,5-dimetil-2-morfolinol ve etkili dengeleyici miktarda alginik asit içeren oral dozaj formülasyonları.

Country Status (17)

Country Link
EP (1) EP1117407A1 (tr)
JP (1) JP2002525328A (tr)
KR (1) KR20010075385A (tr)
CN (1) CN1328459A (tr)
AR (1) AR022673A1 (tr)
AU (1) AU6087399A (tr)
BR (1) BR9914096A (tr)
CA (1) CA2345638A1 (tr)
CZ (1) CZ20011142A3 (tr)
HU (1) HUP0103459A2 (tr)
IL (1) IL142054A0 (tr)
MA (1) MA26693A1 (tr)
NO (1) NO20011555D0 (tr)
PE (1) PE20001087A1 (tr)
PL (1) PL346877A1 (tr)
TR (1) TR200100863T2 (tr)
WO (1) WO2000018406A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597969A (en) * 1982-04-05 1986-07-01 Merck Sharp & Dohme Stabilization of unstable drugs or food supplements
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use

Also Published As

Publication number Publication date
PL346877A1 (en) 2002-03-11
CA2345638A1 (en) 2000-04-06
AR022673A1 (es) 2002-09-04
BR9914096A (pt) 2001-07-31
CZ20011142A3 (cs) 2001-09-12
JP2002525328A (ja) 2002-08-13
WO2000018406A1 (en) 2000-04-06
HUP0103459A2 (hu) 2002-01-28
NO20011555L (no) 2001-03-27
PE20001087A1 (es) 2000-10-20
EP1117407A1 (en) 2001-07-25
AU6087399A (en) 2000-04-17
IL142054A0 (en) 2002-03-10
MA26693A1 (fr) 2004-12-20
KR20010075385A (ko) 2001-08-09
NO20011555D0 (no) 2001-03-27
CN1328459A (zh) 2001-12-26

Similar Documents

Publication Publication Date Title
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
BE2011C013I2 (tr)
MA27153A1 (fr) Formulations pharmaceutiques de derives de platine
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
DE69940769D1 (de) Orale flüssige zusammensetzungen
TR200200951T2 (tr) Farmasötik kompozisyonlar
DE60022180D1 (de) Dentales produkt gegen zahnstein und betreffende methode
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
MY125821A (en) Pharmaceutical composition of topiramate
TR200100812T2 (tr) Akut ağrı tedavisi için fentanil kompozisyon.
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
MY141584A (en) Pharmaceutical uses of bisphosphonates
MXPA05009103A (es) Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
PL346764A1 (en) New oral formulation for 5-ht4
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
CY1106105T1 (el) Αλας μεγλουμινης ενος συγκεκριμενου κινολινοκαρβοξυλικου οξεως ενepγου επι των υποδοχεων nmda
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
TR200100863T2 (tr) (2S,3S,5R)-2-(3,5-Diflorofenil)-3,5-dimetil-2-morfolinol ve etkili dengeleyici miktarda alginik asit içeren oral dozaj formülasyonları.
MXPA04004907A (es) Composiciones de acetaminofen.
AP2001002369A0 (en) Pharmaceutical complex.
Hannig et al. Recovery of peroxides in saliva during home bleaching–influence of smoking